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Summary.-Female C3H/HeJ mice bearing intramuscularly transplanted KHT
sarcomas were treated with a single dose of 1,3-bis (2-chloroethyl)-l-nitrosourea
(BCNU, 30 mg/kg, i.p.) alone or in combination with a single dose of misonidazole
(MISO, 1-0 mg/g, i.p.) or its desmethylated metabolite Ro-05-9963 (2.0 mg/g, i.p.).
The effectiveness of drug therapy was assessed by a tumour growth-delay assay (i.e.
measuring the median time required for tumours to grow to treatment size x4). The
relative efficacy of administering the nitroimidazoles in various schedules ranging
from 12 h before to 12 h after BCNU administration also was evaluated.
Untreated control KHT tumours grew to the initial size x4 in a median time of
4 days. No significant growth delay was seen in mice treated with either nitro-
imidazole alone, whilst treatment with BCNU alone produced a median growth delay
of 7 days. Combination chemotherapy with 9963 administration 3 h after BCNU
significantly increased the median tumour growth delay to 9 days. However, no
significant growth delay was produced in any of the other combinations of these
agents. The median growth delay was significantly reduced to 5 days when MISO
was administered 3 h before BCNU, whereas MISO administered simultaneously
3, 6, or 12 h after BCNU significantly enhanced delays (-9 days).
These results indicate that both MISO and 9963 may be combined with con-
ventional therapeutic agents, in this particular case a nitrosourea, to produce an
enhanced tumour response. The production of such a response appears to be nitro-
imidazole as well as schedule dependent.
THE radioprotective effect of hypoxia
has been well established and the presence
ofoxygen-deficient cells has been shown to
limit tumour control by single and frac-
tionated doses ofradiation in manyanimal
tumour models. More recently, hypoxic
cells in EMT-6 spheroids (Sutherland et
al., 1978, 1979) hypoxic, exponential-
phase cells in monolayer culture (Roizin-
Towle & Hall, 1978; Smith et al., 1979;
Sutherland et al., 1978, 1979) as well as
hypoxic tumour cells in vivo (Hill &
Stanley, 1975; Hill & Bush, 1977) have
been shown to be refractory to treatment
with several conventional cancer chemo-
therapeutic agents. Realization of the
potential significance of hypoxic cells in
limiting the effectiveness of conventional
chemotherapy has led to the design and
evaluation ofexperimental protocols com-
bining commonly used anti-tumour drugs
with nitroimidazoles, which, in addition
to sensitizing hypoxic cells to radiation,
have been shown to be preferentially cyto-
toxictohypoxictumourcells (Sridharetal.,
1976; Brown, 1977; Conroy et al., 1980;
Mohindra & Rauth, 1976; Moore et al.,
1976; Olive & Durand, 1978; Stratford &
Adams, 1977; Sutherland, 1974; Suther-
land et al., 1980). For example, Sutherland
et al. (1979) have reported that pretreat-
ment with misonidazole (MISO) before
Adriamycin significantly reduced the
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spheroids. Iso-effect analysis of these data
suggested that the combination of Adria-
mycin and MISO resulted in apparent
supra-additive cytotoxicity (Sutherland et
al., 1980). Likewise, Rose et al. (1980) have
demonstrated enhanced cytotoxicity in
Lewis lung tumours treated in vivo with
combinations ofMISOandvarious alkylat-
ing agents. We therefore designed experi-
ments to evaluate the relative effectiveness
of several drug administration schedules
combining MISO, or its desmethylated
metabolite Ro-05-9963 (9963) with the
clinically useful alkylating agent 1,3-bis-
(2-chloroethyl)-1-nitrosourea (BCNU) in
the treatment of KHT tumours in vivo.
MATERIALS AND METHODS
For these experiments 2 x 105 KHT (Kall-
man et al., 1967) tumour cells were injected
i.m. into the right calf of 8-12-week-old
female C3H/HeJ mice. Animals were sorted
and randomized into the appropriate control
and experimental groups when the tumours
had grown to 0-2 g. BCNU (30 mg/kg) and
MISO (1.0 mg/g) or 9963 (2-0 mg/kg) were
injected i.p. according to the administration
schedules outlined in Tables I and II. BCNU
was initially dissolved in 100% ethanol at a
concentration of 30 mg/ml, and then diluted
to a final concentration of 1-5 mg/ml with
physiological saline immediately before in-
jection. MISO and 9963 were dissolved in
PBS at concentrations of 20 and 40 mg/ml
respectively.
The relative effectiveness of the various
drug-treatment combinations was evaluated
in a tumour growth-delay assay. Tumour size
was measured daily by passing the tumour-
bearing leg through a series of increasing
diameter holes in a Plexiglass rod. This
measurement was then converted to a tumour
weight by using a calibration curve obtained
by excising and weighing tumours of meas-
ured diameters from the legs of untreated
animals (Siemann et at., 1977). Growth delay
was then determined by measuring the
difference in time required fortreated tumours
to grow to 4 x the initial treatment size
(weight) relative to that required for un-
treated tumours.
Five to 7 animals were routinely included
in the control and treatment groups for each
experiment. Groups listed in Tables I and II
as having n> 7 represent the pooled data from
2-4 replicate experiments. Drug-related toxic
deaths refer to the number of animals which
died during the tumour-measurement period
without metastatic tumour involvement of
the lungs.
The time required for individual tumours
to grow to a size 4 x the treatment size was
not normally distributed within some of the
treatment groups; thus, the results are re-
ported and compared using median growth-
delay values. The non-parametric Wilcoxon
rank-sum test was used for statistical
analysis.
RESULTS
Untreated KHT tumours grew to 4 x
their initial size in a median time of 4 days
(Figs 1 and 2, Tables I and II). The
growth oftumours in animals treated with
a single dose of MISO or 9963 alone was
not significantly different (P> 0.05) from
that of untreated tumours (Tables I and
II). KHT tumours treated in vivo with a
single 30mg/kg dose of BCNU grew to 4 x
initial treatment size in 11 days, a median
delay of 7 days. The pattern of tumour
growth as a function of time after ad-
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FiGs 1 and 2.-Semi-log plots of KHT
tumour wt as a function of time after
treatment. The data plotted are the
tumour growth curves for the median
mouse from the pooled data from 2-4
replicate experiments.
Fia. 1.-Combination chemotherapy with
9963 and BCNU. The curves for all other
9963-BCNU combinations not shown in
this graph fall within the shaded area.
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FIG. 2.-Tumour regrowth after treatment
with MISO and BCNU. MISO administered
3 h before BCNU significantly reduced the
growth delayproduced byBCNUalone. Re-
growth of tumours in animals treated with
MISO 3, 6 or 12 h after BCNU was similar
to that for tumours treated with BCNU
and MISO simultaneously, and have been
omitted for clarity.
ministration of either of the nitroimid-
azoles was virtually identical to that of
the controls (Figs 1 and 2). After treat-
ment with BCNU alone or in combination-
with the nitroimidazoles, tumours con-
tinued to grow for 2-3 days. This period
of initial tumour growth was followed by
variable periods oftumour regression, and
ultimately by tumour regrowth which
paralleled that of untreated tumours
(Figs 1 and 2).
The results of experiments designed to
evaluate the relative efficacy of combined
treatments with BCNU and 9963 are
summarized in Table I and Fig. 1. A
median tumour growth delay of 9 days
was produced when animals were treated
with 9963 3 h after BCNU. This response
was significantly greater than that after
BCNU alone (P< 0 01). However, tumour
growth delay following all other combina-
tions of 9963 and BCNU was not signifi-
cantly different from growth delay pro-
duced by BCNU alone.
The results of the combination MISO-
BCNU experiments are summarized in
Table II and Fig. 2. It is readily apparent
that the results obtained by combining
BCNU with MISO did not always parallel
those produced by similar combinations
with 9963. For example, whereas pretreat-
ment with 9963 failed to significantly alter
TABLE I.-Combination chemotherapy: BCNU and Ro-05-9963. Median day for KHT
tumours to reach 4 x mean initial tumour size
Treatment
group
1. Control
2. 9963 (2 mg/g, i.p.)
3. BCNU (30 mg/kg, i.p.)
4. 9963-12 h--BCNU
5. 9963-6 h-+BCNU
6. 9963-3 h-*BCNU
7. 9963-1 h-.BCNU
8. 9963 +BCNU (simultaneously)
9. BCNU-1 h-+9963
10. BCNU-3 h-.9963
11. BCNU-6 h- 9963
12. BCNU-12 h-.9963
Median day Confidence*
to interval
n 4 x (%)
27 4-0 3.5-4-5
(95%)
16 3-75 30-5-0
(98%)
24 11.0 10-0-12*0
(98%)
7 10*25 9-0-12-0
(97%)
5
19 12-0 10-0-13-0
(98%)
7 10-75 8-5-13-0
(97%)
14 10-0 9-0-12-0
(94%)
7 11-0 10-0-12'0
(97%)
19 13-0 12-5-15-0
(95%)
7 10-0 10-0-13-0
(97%)
3 11-0
Animalt
deaths
0
0
0
1
2
3
1
0
0
2
1
0
Pt
Vs 1
Vs3
>0-05
<0-01
>0-05
> 0 05
>0*05
>0.05
> 0 05
< 0-01
> 0*05
* From Noether (1971) Introduction toStatistics A Fresh Approach. Boston: Houghton Mifflin.
t During the measurement period.
t Wilcoxon Rank Test.
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TABLE II.-Combination chemotherapy: B(CNU and MISO. Median day for KHT
tumours to reach 4 x mean initial tumour size
Treatment group
1. Control
2. MISO (1 mg/g, i.p.)
3. BCNU (30 mg/kg, i.p.)
4. MISO 12h-BCNU
5. MISO-6 h-BCNU
6. MISO 3 h-+BCNU
7. MISO 1 h-BCNU
8. MISO +BCNU (simultaneously)
9. BCNU-1 h-+MISO
10. BCNU 3 h-+MISO
1.BCNU 6 h-MISO
12. BCNU-12 h-+MISO
Median day Confidence*
to interval
n 4x (%)
27 4*0 3-5-4-5
(95%)
12 4-25 3-5-5-0
(96%)
24 110 10*0-12*0
(98%)
7 11-5 7-5-13.0
(98%)
7 10-5 90-13-0
(98%)
21 9*0 8*5-11*5
(96%)
5 11*0 8-0-12-0
(94%)
21 13-0 12-0-15O0
(97%)
7 11-5 10*0-12-0
(98%)
21 13-0 12-0-14.0
(96%)
7 13-0 10 0-18-0
(94%)
6 14-0 11*5-16-0
(94%)
Animalt
deaths
0
0
0
0
0
0
0
0
1
2
1
Vs 1 {
vs 3 1
Pt
> 0 05
<0-01
>005
>005
<0-01
> 0*05
<0-01
>0*05
<0-01
<005
<005
* From Noether (1971) Introduction toStatistics-A Fresh Approach. Boston: Houghton Mifflin.
t During the measurement period.
t Wilcoxon Rank Test.
the growth of tumours subsequently
treated with BCNU, administration of
MISO 3 h before BCNU significantly
reduced tumour growth delay. Simul-
taneous administration of BCNU and
MISO significantly (P < 0 01) enhanced
tumour growth delay, whereas no addi-
tional delay was produced with simul-
taneous 9963 administration. However,
as with 9963, tumour growth delay
was significantly enhanced when MISO
was injected 3 h after BCNU. In addi-
tion, MISO combined 6 or 12 h after
BCNU also significantly enhanced the
response of KHT tumour, in contrast to
the results obtained with the correspond-
ing 9963-BCNU combinations.
The enhanced tumour response pro-
duced when MISO was administered 6 or
12 h after BCNU was associated with an
increased number of drug-related deaths
(24.6% and 16.7% respectively). Whilst
10-5% of the animals treated with BCNU
followed 3 h later by 9963 died of causes
attributed to drug toxicity, only 1/21
animals (4.8%) treated with MISO 3 h
after BCNU, and 0/21 animals treated
simultaneously with MISO and BCNU
died from drug toxicity. No animals died
after a single dose of any of the drugs
administered alone.
DISCUSSION
Chemotherapy combining clinically used
anti-tumour agents to kill aerobic cycling
cells with compounds selectively targeted
against cells within the hypoxic compart-
ment of tumours has been proposed
(Sutherland, 1974; Sutherland et al., 1976)
as a means of overcoming the recently
demonstrated chemoresistance of hypoxic
mammalian cells. MISO, an electron-
affinic nitroimidazole currently being
clinically evaluated as a radiation sensi-
tizer, is preferentially cytotoxic to hypoxic
cells (Sridhar et al., 1976; Brown, 1977;
Conroy et al., 1979; Stratford & Adams,
1977; Sutherland et al., 1980) and is
capable of enhancing the cytotoxicity of
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certain anti-tumour agents to cells in
EMT-6 spheroids (Sutherland et al., 1979,
1980) and Lewis lung tumours in vivo
(Rose et al., 1980). In order to exploit
this type of enhanced cytotoxicity thera-
peutically most efficiently, it is essential
to evaluate various drug administration
schedules. In addition, it is conceivable
that potentially less toxic nitroimidazoles,
such as 9963, may also be advantageously
administered in conjunction with con-
ventional chemotherapeutic drugs. There-
fore, we designed experiments to investi-
gate the response of KHT tumours in vivo
to a series of treatment combinations of
MISO, or its desmethylated metabolite
Ro-05-9963, with BCNU, which has been
shown to be relatively ineffective against
the hypoxic cells of B16 melanomas (Hill
& Stanley, 1975).
Although neither MISO nor 9963 de-
layed the growth of KHT tumours when
administered alone, both were capable of
enhancing tumour response to BCNU
treatment, provided they were injected at
appropriate times relative to BCNU
administration. MISO significantly im-
proved tumour response in more of the
combinations evaluated (4/9) than did
9963 (1/9). Interestingly, however, MISO
reduced BCNU effectiveness when given
3 h before BCNU, whereas a similar com-
bination of 9963 produced a slight, though
not significant, increase in growth delay.
These results emphasize the importance
of considering the drug injection schedule
when evaluating combination chemo-
therapy with nitroimidazoles. They fur-
ther demonstrate that an effective com-
bination for one nitroimidazole is not
necessarily predictive of similar effective-
ness when the combination includes a
different nitroimidazole. The effectiveness
ofcombinednitroimidazole-BCNU chemo-
therapy treatment of KHT tumours in
vivo is, therefore, both nitroimidazole and
schedule dependent.
The enhancement of tumour growth
delay was similar for all effective drug
combinations. The additional growth delay
of 2 days is equivalent to about one
doubling time for KHT tumours over the
size range used in these studies. Although
killing of hypoxic cells by the nitroimid-
azoles is probably partially responsible for
the observed enhancement, it seems likely
that other factors may be involved, par-
ticularly since positive interactions were
only produced in response to simultan-
eous BCNU-MISO administration or to
addition of nitroimidazoles more than
one hour after BCNU. Other poss-
ible contributory factors might include:
altered pharmacokinetics and bioavail-
ability of BCNU or the sensitizers, nitro-
imidazole-induced inhibition of the repair
of sub-lethal or potentially lethal BCNU
damage, BCNU-induced sensitization to
the cytotoxic action of the nitroimid-
azoles, or conversely, nitroimidazole-
induced sensitization to BCNU. In pre-
liminary clonogenic assays we have seen
no evidence for repair of sublethal or
potentially lethal damageinKHTtumours
after BCNU treatment. Therefore, repair
inhibition by the nitroimidazoles does not
seem to be a plausible explanation for our
results. Considering the short plasma half-
life (Oliverio, 1973) of the parental BCNU
compound, it seems improbable that
addition of sensitizer several hours after
BCNU could substantially alter its bio-
availability. However, it is conceivable
that such combinations could profoundly
influence the metabolic detoxification of
reactive daughter products. Prolonged
exposure to cytotoxic, nitrosourea-related
degradation products or alternatively, a
mechanism involving direct or indirect
BCNU-induced sensitization to nitroimid-
azole cytotoxicity, would at the present
seem most consistent with our observa-
tions. Experiments designed to further
evaluate these various possibilities are in
progress.
In spite of encouraging tumour results,
combination chemotherapy with nitro-
imidazoles will prove to be of therapeutic
benefit only if the magnitude of the
enhanced tumour response exceeds the
enhancement ofany normal tissue toxicity
due to such combinations.
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Although the numbers of animals ob-
served were small, in terms of animal
deaths, some of the combinations studied
appeared to be more toxic than might be
expected from a consideration of the
single-agent toxicities. However, in 3
replicate experiments two of the more
effective combinations (MISO given at the
same time as or 3 h after BCNU) resulted
in little or no drug-related lethality.
We have performed preliminary experi-
ments to further evaluate the normal
tissue toxicity resulting from simul-
taneous treatment with MISO and BCNU.
Depression of the peripheral white-cell
count, a major toxicity associated with
BCNU treatment (Katz & Glick, 1979)
was not significantly different between
groups of animals treated with BCNU
alone or in combination with MISO. Like-
wise, rotorod performance, a measure of
peripheral neuropathy (Conroy et al.,
1979) one of the major dose-limiting
toxicities experienced in clinical trials
with MISO (Dische et al., 1978) was not
significantly different between groups of
animals which received MISO alone or in
conjunction with BCNU. Experiments
designed to quantitate and compare
tumour and normal tissue enhancement
ratios are in progress. However, our
current results are consistent with those
of Rose et al. (1980) suggesting that com-
bination chemotherapy including nitro-
imidazoles may enhance tumour response
without equally enhancing normal tissue
toxicity.
In conclusion, we have demonstrated
that combining BCNU with the radiation
sensitizers misonidazole and Ro-05-9963
can enhance KHT tumour response as
determined with a growth-delay assay.
The production of such a response is
nitroimidazole and schedule dependent.
Some of the combinations which were
effective in enhancing tumour response
did not increase drug-related deaths, thus
suggesting a potential therapeutic advant-
age. This therapeutic approach may be
particularly advantageous in the treat-
ment of widespread metastatic disease,
where localized radiation therapy is im-
practical and the success of conventional
chemotherapy is limited by the presence
of chemoresistant hypoxic tumour cells
and overlapping normal tissue toxicities.
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